for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regulus Therapeutics Inc

RGLS.OQ

Latest Trade

0.80USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.54

 - 

3.14

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.80
Open
--
Volume
--
3M AVG Volume
3.35
Today's High
--
Today's Low
--
52 Week High
3.14
52 Week Low
0.54
Shares Out (MIL)
20.82
Market Cap (MIL)
16.66
Forward P/E
-0.86
Dividend (Yield %)
--

Next Event

Q3 2019 Regulus Therapeutics Inc Earnings Release

Latest Developments

More

Regulus Therapeutics Says Q2 Loss Per Share $0.30

Regulus Therapeutics Appoints Cris Calsada As Chief Financial Officer

Regulus Therapeutics Announces Rgls4326 Program Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Regulus Therapeutics Inc

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Industry

Biotechnology & Drugs

Contact Info

10628 Science Center Dr Ste 225

+1.858.2026300

http://www.regulusrx.com/

Executive Leadership

Stelios B. Papadopoulos

Chairman of the Board

Joseph P. Hagan

President, Chief Executive Officer, Director

Crispina Calsada

Chief Financial Officer

Daniel Penksa

Principal Accounting Officer, Controller

Kathryn J. Collier

Director

Key Stats

2.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-18.600

2017

-11.520

2018

-5.590

2019(E)

-0.925
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.44
Price To Book (MRQ)
3.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
318.53
LT Debt To Equity (MRQ)
4.22
Return on Investment (TTM)
-230.01
Return on Equity (TTM)
-72.43

Latest News

BRIEF-Regulus Reports Q1 Loss Per Share $0.15

* REGULUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PIPELINE PROGRESS

BRIEF-Kathryn Collier Joins Regulus Board Of Directors

* KATHRYN J. COLLIER JOINS REGULUS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Regulus Qtrly Net Loss Per Share $0.14

* REGULUS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PIPELINE UPDATE

BRIEF-Regulus Therapeutics Files For Mixed Shelf Of Up To $150 Mln

* REGULUS THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text: (http://bit.ly/2rQDgcO) Further company coverage:

BRIEF-Regulus Therapeutics Q3 loss per share $0.18

* Regulus reports third quarter 2017 financial results and recent events

BRIEF-Regulus Q3 loss per share $0.18

* Regulus reports third quarter 2017 financial results and recent events

BRIEF-Growth Equity Opportunities reports 11.3 pct stake in Regulus Therapeutics

* Growth Equity Opportunities V reports 11.3 percent stake in Regulus Therapeutics Inc as of July 24 - SEC filing Source text: (http://bit.ly/2u4yxoS) Further company coverage:

BRIEF-Regulus Therapeutics Q2 loss per share $0.41

* Regulus reports second quarter 2017 financial results and recent events

BRIEF-Broadfin Capital reports 5.65 pct passive stake in Regulus Therapeutics - SEC filing

* Broadfin Capital LLC reports 5.65 percent passive stake in Regulus Therapeutics Inc as of July 20, 2017 - SEC filing Source text: (http://bit.ly/2vSFqWv) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Aptuit announces strategic provider agreement with Regulus Therapeutics

* Aptuit announces strategic provider agreement with Regulus Therapeutics Source text for Eikon: Further company coverage:

BRIEF-EcoR1 Capital reports 9.6 pct passive stake in Regulus Therapeutics

* EcoR1 Capital LLLC reports a 9.6 percent passive stake in Regulus Therapeutics Inc as of May 17 - SEC filing Source text for Eikon: (http://bit.ly/2r8sCMk) Further company coverage:

BRIEF-Regulus reports Q4 loss per share $0.38

* Regulus reports fourth quarter 2016 financial results and pipeline update

BRIEF-Regulus Therapeutics announces continuation of RG-101 clinical hold

* Received written communication from FDA that clinical development program for RG-101 remains on clinical hold

BRIEF-Regulus reports third quarter 2016 financial results

* Regulus reports third quarter 2016 financial results Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up